{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:07:25Z","timestamp":1783004845110,"version":"3.54.5"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["CA200841"],"award-info":[{"award-number":["CA200841"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["ZIA BC 011115"],"award-info":[{"award-number":["ZIA BC 011115"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["ZIA BC 011657"],"award-info":[{"award-number":["ZIA BC 011657"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.omtn.2025.102610","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T02:49:01Z","timestamp":1750128541000},"page":"102610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["microRNA-497-5p-based screening identifies a novel synthetic lethal-type interaction via PKMYT1 and WEE1 in pleural mesothelioma"],"prefix":"10.1016","volume":"36","author":[{"given":"Nathanael","family":"Pruett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sierra","family":"Wilferd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes Y.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlize","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Schrump","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"Plaisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4016-1434","authenticated-orcid":false,"given":"Chuong D.","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102610_bib1","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jtho.2021.12.014","article-title":"The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification","volume":"17","author":"Sauter","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.omtn.2025.102610_bib2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.lungcan.2015.03.005","article-title":"Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales","volume":"88","author":"Beckett","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.omtn.2025.102610_bib3","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2025.102610_bib4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2025.102610_bib5","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omtn.2025.102610_bib6","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jtho.2023.11.014","article-title":"Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso","volume":"19","author":"McNamee","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.omtn.2025.102610_bib7","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omtn.2025.102610_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.1490","article-title":"Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma","volume":"5","author":"Meirson","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.omtn.2025.102610_bib9","article-title":"Promising therapeutic potential of tumor suppressor microRNAs for malignant pleural mesothelioma","volume":"8","author":"Dixit","year":"2022","journal-title":"J. Cancer Metastasis Treat."},{"key":"10.1016\/j.omtn.2025.102610_bib10","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"van Zandwijk","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omtn.2025.102610_bib11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3389\/fcell.2020.00427","article-title":"miR-15\/107 microRNA Gene Group: Characteristics and Functional Implications in Cancer","volume":"8","author":"Turco","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omtn.2025.102610_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317692204","article-title":"The miR-30 family: Versatile players in breast cancer","volume":"39","author":"Yang","year":"2017","journal-title":"Tumour Biol."},{"key":"10.1016\/j.omtn.2025.102610_bib13","doi-asserted-by":"crossref","first-page":"8163","DOI":"10.1093\/nar\/gkr532","article-title":"Specific sequence determinants of miR-15\/107 microRNA gene group targets","volume":"39","author":"Nelson","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102610_bib14","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41588-023-01321-1","article-title":"Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity","volume":"55","author":"Mangiante","year":"2023","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2025.102610_bib15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3389\/fonc.2020.00105","article-title":"Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future","volume":"10","author":"Reid","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omtn.2025.102610_bib16","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/annonc\/mdt412","article-title":"Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma","volume":"24","author":"Reid","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omtn.2025.102610_bib17","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/JTO.0b013e31820db125","article-title":"MicroRNAs dysregulation in human malignant pleural mesothelioma","volume":"6","author":"Balatti","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.omtn.2025.102610_bib18","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1038\/s41598-017-02694-0","article-title":"Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism","volume":"7","author":"De Santi","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2025.102610_bib19","doi-asserted-by":"crossref","DOI":"10.23937\/2378-3419\/1410141","article-title":"Circulating Mir-497-5p as a Potential Non-Invasive Molecular Marker for Diagnosis and Prognosis in Mesothelioma","volume":"7","author":"Majed Al","year":"2020","journal-title":"Int. J. Cancer Clin. Res."},{"key":"10.1016\/j.omtn.2025.102610_bib20","doi-asserted-by":"crossref","first-page":"55900","DOI":"10.18632\/oncotarget.10152","article-title":"miR-497 expression, function and clinical application in cancer","volume":"7","author":"Yang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.omtn.2025.102610_bib21","doi-asserted-by":"crossref","DOI":"10.1177\/0963689719897061","article-title":"MicroRNA-497-5p Functions as a Modulator of Apoptosis by Regulating Metadherin in Ovarian Cancer","volume":"29","author":"Liu","year":"2020","journal-title":"Cell Transplant."},{"key":"10.1016\/j.omtn.2025.102610_bib22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12935-018-0601-4","article-title":"miR-145 and miR-497 suppress TGF-beta-induced epithelial-mesenchymal transition of non-small cell lung cancer by targeting MTDH","volume":"18","author":"Yin","year":"2018","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.omtn.2025.102610_bib23","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.tranon.2019.03.005","article-title":"Metadherin Is a Prognostic Apoptosis Modulator in Mesothelioma Induced via NF-kappaB-Mediated Signaling","volume":"12","author":"Zhang","year":"2019","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.omtn.2025.102610_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcad029","article-title":"Synthetic lethal interaction between WEE1 and PKMYT1 is a target for multiple low-dose treatment of high-grade serous ovarian carcinoma","volume":"5","author":"Benada","year":"2023","journal-title":"NAR Cancer"},{"key":"10.1016\/j.omtn.2025.102610_bib25","series-title":"Regulatory Non-coding RNAs","first-page":"29","article-title":"A biochemical approach to identify direct microRNA targets","author":"Subramanian","year":"2015"},{"key":"10.1016\/j.omtn.2025.102610_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/science.aav1741","article-title":"The biochemical basis of microRNA targeting efficacy","volume":"366","author":"McGeary","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102610_bib27","first-page":"D845","article-title":"The DisGeNET knowledge platform for disease genomics: 2019 update","volume":"48","author":"Pinero","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102610_bib28","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1158\/2767-9764.CRC-22-0168","article-title":"Replication stress defines distinct molecular subtypes across cancers","volume":"2","author":"Takahashi","year":"2022","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.omtn.2025.102610_bib29","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","article-title":"Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R\u03b3null mice engrafted with mobilized human hemopoietic stem cells","volume":"174","author":"Shultz","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.omtn.2025.102610_bib30","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/j.ymthe.2019.05.020","article-title":"MicroRNA-215-5p Treatment Suppresses Mesothelioma Progression via the MDM2-p53-Signaling Axis","volume":"27","author":"Singh","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102610_bib31","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/s41565-021-00961-w","article-title":"Surface-fill hydrogel attenuates the oncogenic signature of complex anatomical surface cancer in a single application","volume":"16","author":"Majumder","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.omtn.2025.102610_bib32","article-title":"Systematic integration of protein-affecting mutations, gene fusions, and copy number alterations into a comprehensive somatic mutational profile","volume":"3","author":"Striker","year":"2023","journal-title":"Cell Rep. Methods"},{"key":"10.1016\/j.omtn.2025.102610_bib33","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.4103\/1673-5374.257514","article-title":"Challenges in microRNAs' targetome prediction and validation","volume":"14","author":"Rojo Arias","year":"2019","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.omtn.2025.102610_bib34","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1158\/1535-7163.MCT-19-0724","article-title":"CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma","volume":"19","author":"Xu","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.omtn.2025.102610_bib35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13045-020-0844-0","article-title":"MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC","volume":"13","author":"Sun","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omtn.2025.102610_bib36","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/s41419-020-02812-3","article-title":"Inhibition of miR-1193 leads to synthetic lethality in glioblastoma multiforme cells deficient of DNA-PKcs","volume":"11","author":"Zhang","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.omtn.2025.102610_bib37","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/cdd.2015.165","article-title":"Molecular profiling reveals primary mesothelioma cell lines recapitulate human disease","volume":"23","author":"Chernova","year":"2016","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.omtn.2025.102610_bib38","doi-asserted-by":"crossref","first-page":"L652","DOI":"10.1152\/ajplung.00141.2020","article-title":"Normal mesothelial cell lines newly derived from human pleural biopsy explants","volume":"319","author":"Pruett","year":"2020","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.omtn.2025.102610_bib39","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.omtn.2025.102610_bib40","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/sj.bjc.6606076","article-title":"The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis","volume":"104","author":"Gee","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omtn.2025.102610_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000898","article-title":"Evidence based selection of housekeeping genes","volume":"2","author":"de Jonge","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2025.102610_bib42","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1101\/gr.133991.111","article-title":"A miRNA-regulatory network explains how dysregulated miRNAs perturb oncogenic processes across diverse cancers","volume":"22","author":"Plaisier","year":"2012","journal-title":"Genome Res."},{"key":"10.1016\/j.omtn.2025.102610_bib43","doi-asserted-by":"crossref","DOI":"10.1093\/genetics\/iyad031","article-title":"The Gene Ontology knowledgebase in 2023","volume":"224","author":"Gene Ontology Consortium","year":"2023","journal-title":"Genetics"},{"key":"10.1016\/j.omtn.2025.102610_bib44","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/jso.2930310402","article-title":"Tumor measurement in the nude mouse","volume":"31","author":"Euhus","year":"1986","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.omtn.2025.102610_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110569","article-title":"Genome-wide identification and analysis of prognostic features in human cancers","volume":"38","author":"Smith","year":"2022","journal-title":"Cell Rep."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125001647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125001647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:33:07Z","timestamp":1777321987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253125001647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2162253125001647"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102610","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"microRNA-497-5p-based screening identifies a novel synthetic lethal-type interaction via PKMYT1 and WEE1 in pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102610","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102610"}}